No Data
Express News | Shenzhen Stock Exchange: Hengrui Pharmaceuticals has been added to the list of eligible securities for the Hong Kong Stock Connect.
Breaking news! Giants are strongly bullish.
China's "Top Ten Giants".
Hengrui Medicine (01276.HK) has received approval for multiple products to initiate clinical trials.
Hengrui Medicine (01276.HK) announced that it has received approval from the National Medical Products Administration for clinical trials of SHR2554 tablets, injectable SHR-A1811, injectable SHR-A2102, injectable Adalimumab solution, injectable SHR-A1904, and SHR1701 injectable solution, which will soon commence clinical trials. The group stated that as of now, the research and development investment in projects related to SHR2554 tablets is approximately 0.179 billion yuan (RMB), and for projects related to injectable SHR-A1811, the cumulative R&D investment is approximately 1.17 billion yuan; projects related to injectable SHR-A2102 are cumulatively.
The Hang Seng Index rose 292 points, with domestic banks and insurers leading the gains, and China Life increasing by over 4%.
In June, the one-year and five-year LPR in Mainland China remained unchanged as expected. U.S. President Trump stated that a decision on whether to attack Iran would be made within two weeks. U.S. stock index futures rebounded, and Hong Kong stocks rose. The Hang Seng Index opened 53 points higher, and the gains expanded, reaching an increase of 300 points to 23,538 points. It ultimately rose by 292 points, or 1.3%, closing at 23,530 points; the Hang Seng China Enterprises Index rose by 116 points, or 1.4%, closing at 8,527 points; the Hang Seng TECH Index rose by 44 points, or 0.8%, closing at 5,133 points. The total market turnover for the day was 222.423 billion yuan. The market anticipates that Mainland China may independently lower the five-year LPR in the second half of the year, affecting China Mainland Banking with ICBC (01398).
Hengrui Pharmaceuticals (600276.SH): Received the drug clinical trial approval notice.
Gelonghui reported on June 20 that Hengrui Pharmaceuticals (600276.SH) announced that the company and its subsidiaries Suzhou Shengdiya CNI Biomedicine Index Co., Ltd., Shanghai Hengrui Pharmaceuticals Co., Ltd., and Shanghai Shengdi Pharmaceuticals Co., Ltd. have received the approval notice for clinical trials from the National Medical Products Administration for SHR2554 tablets, injectable SHR-A1811, injectable SHR-A2102, Adalimumab injection, injectable SHR-A1904, and SHR-1701 injection, which will commence clinical trials in the near future.
Hengrui Pharmaceuticals (600276) Company Brief Review Report: The commercialization of innovative drugs continues to deliver results, and the Global Strategy has ushered in new opportunities.
Event: The company announced on May 23 that it has completed the issuance of H shares and achieved listing on the exchange, and announced the full exercise of the over-allotment option on June 19. This supplements the company's Cash flow and ensures long-term stable development. Consider exercising the over-allotment option.
